Family Support Tool Intervention for Critical Illness
(FST Trial)
Trial Summary
What is the purpose of this trial?
This trial tests a program that helps families of critically ill older adults by offering meetings with doctors and an online tool. It aims to improve communication, help families make informed decisions, and reduce their stress.
Will I have to stop taking my current medications?
The trial protocol does not specify whether participants must stop taking their current medications.
What data supports the effectiveness of the Family Support Tool Intervention (FST) treatment for critical illness?
Is the Family Support Tool Intervention safe for humans?
How is the Family Support Tool Intervention unique compared to other treatments for critical illness?
Research Team
Douglas B White, MD, MAS
Principal Investigator
University of Pittsburgh
Eligibility Criteria
This trial is for critically ill older adults (age ≥60) in the ICU with a high risk of death or severe long-term impairment, and their family surrogates. Patients must lack decision-making capacity and have at least a 50% chance of dying or needing significant help with daily activities. Surrogates must be adults, speak English, able to use the internet, and not involved in conflicting studies.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Proactive family meetings within 48 hours of enrollment and every 5-7 days thereafter. Family members complete sections of an interactive web-based tool upon study enrollment, before family meetings, and any other time they wish.
Follow-up
Participants are monitored for patient and family-centeredness of care, functional status, and other outcomes at 3 and 6 months after hospital discharge.
Treatment Details
Interventions
- Multi-component Family Support Intervention (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pittsburgh
Lead Sponsor
David Apelian
University of Pittsburgh
Chief Executive Officer since 2019
PhD in Molecular Biology from Rutgers University, MD from the University of Medicine and Dentistry of New Jersey, MBA from Quinnipiac University
Pamela D. Garzone
University of Pittsburgh
Chief Medical Officer
PhD in Clinical Science from the University of Pittsburgh
University of North Carolina, Chapel Hill, NC, USA
Collaborator
VA Pittsburgh Healthcare System
Collaborator
Pittsburgh VA Medical Center-University Drive
Collaborator
Oregon Health and Science University
Collaborator
John Hunter
Oregon Health and Science University
Chief Medical Officer since 2024
MD, specific details unavailable
Ann Madden Rice
Oregon Health and Science University
Chief Executive Officer
FACHE certification, extensive leadership experience in academic health centers
Baystate Medical Center
Collaborator
Peter Banko
Baystate Medical Center
Chief Executive Officer
MBA from Stanford University
Dr. Yvonne Cheung
Baystate Medical Center
Chief Medical Officer since 2024
MD from Columbia University, MPH from Harvard School of Public Health, MBA from University of Massachusetts Amherst
Duke University
Collaborator
Mary E. Klotman
Duke University
Chief Executive Officer since 2017
MD from Duke University School of Medicine
Michelle McMurry-Heath
Duke University
Chief Medical Officer since 2020
MD from Duke University School of Medicine
New York City Health and Hospitals Corporation
Collaborator
University of North Carolina, Chapel Hill
Collaborator
Dr. Peggy P. McNaull
University of North Carolina, Chapel Hill
Chief Medical Officer
MD from Louisiana State University School of Medicine
Dr. Lynne Fiscus
University of North Carolina, Chapel Hill
Chief Executive Officer since 2020
MD from Georgetown University, MPH from UNC
National Institute on Aging (NIA)
Collaborator
Dr. Richard J. Hodes
National Institute on Aging (NIA)
Chief Executive Officer since 1993
MD from Harvard Medical School
Dr. Marie Bernard
National Institute on Aging (NIA)
Chief Medical Officer
MD from Harvard Medical School